Press

PharmAla Biotech completes filing of Patent application for 6 MDMA analogs

Aug 29 • 4 min read

PharmAla Biotech (CSE: MDMA) is pleased to announce the filing of a key Patent Cooperation Treaty (PCT) application, containing 6 Novel Chemical Entities (NCEs). The application claims priority to, and benefit of a United States provisional patent application filed August 20, 2021. This PCT application disclosed novel compositions of MDMA and analogs thereof which may be used to alleviate…

MindMed Completes 1-for-15 Reverse Share Split

Aug 29 • 3 min read

Mind Medicine Inc. (NASDAQ: MNMD | NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that its previously announced 1-for-15 reverse share split of the Company’s common shares, par value $0.001, became effective after the close of markets on August 26, 2022, with trading expected to begin on a…

Love Pharma Delivers Letter to Shareholders

Aug 29 • 5 min read

LOVE Pharma Co. (CSE: LUV | FSE: G1Q0), the Company is pleased to provide the following letter to shareholders, outlining the Company’s advancements with key holdings and its strategy for the future. To the Shareholders of Love Pharma: We welcome this opportunity to provide our shareholders with a comprehensive picture of Love’s efforts in building upon…

PsyBio Therapeutics Reports Second Quarter 2022 Financial Results

Aug 29 • 3 min read

PsyBio Therapeutics Corp. (TSXV: PSYB | OTCQB: PSYBF), a fully integrated and intellectual property driven biotechnology company developing novel psychoactive medicinal candidates targeting the potential treatment of mental health challenges, neurological disorders and other human health conditions, today announced that it has reported its unaudited interim financial results for the three and six month period ended June 30,…

B.More Receives FDA Investigational New Drug Approval for Psilocybin Alcohol Use Disorder Program Phase 2b Clinical Trial

Aug 26 • 2 min read

B.More Inc., a 501(c)(3) non-profit, clinical-stage biopharmaceutical company focused on the development of psychedelic medicines for substance abuse disorders, today announced that the U.S. Food and Drug Administration has approved its IND application to begin a Phase 2b clinical trial to determine the efficacy and safety of synthetic psilocybin (SYNP-101) in treating patients with alcohol use disorder…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435